here are now sufficient data to suggest that lithium is an effective augmentation strategy for patients with major depression who have an inadequate response to all classes of antidepressants (1). A recent metaanalysis supports the efficacy of T3 in treatment-resistant depression (2); these studies involving T3 were in patients taking tricyclic antidepressants, although a recent study supports the efficacy of T3 in SSRI-resistant depression (3). Further, there is some clinical evidence that lithium and T3, which both work as an augmentation strategy in up to 50% of cases (1,2), may be effective in different subgroups of depression patients (4,5). We reasoned that combined lithium and T3 might produce greater improvement in depression scores than either alone and, therefore, carried out a direct comparison of lithium and T3 alone and a combination, using a 2-week, double-blind, placebocontrolled design.
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Methods
Thirty-six subjects attending as outpatients of the Mood Disorders Program at the University of Toronto completed the study. All gave written and oral consent to participate, fulfilled DSM-IV criteria for nonpsychotic, unipolar major depressive disorder, and had normal thyroid function tests, including an ultrasensitive thyrotropin within the normal Objective: To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone.
Methods:
We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant.
range. All subjects had completed a trial of antidepressants at usual dosages (moclobemide 600 to 750 mg daily, nefazodone 150 to 300 mg daily, paroxetine 20 to 60 mg daily, sertraline 100 to 200 mg daily, fluoxetine 30 to 40 mg daily, fluvoxamine 150 to 300 mg daily, and venlafaxine 187.5 to 375 mg daily) for at least 5 weeks. The study was approved by the Institutional Review Board at the University of Toronto.
Subjects received indistinguishable unmarked capsules containing either 37.5 mcg of T3, 600 mg of lithium, a combination of both, or placebo for 2 weeks. The subject's antidepressant was maintained at the same dosage for the duration of the trial. Patients and the trained nurse rater were blind to the group assignment. Blood was drawn for lithium levels in all subjects at the end of the first week, and for those subjects in the 2 lithium arms, the dosage of lithium was increased to 900 mg daily if the level was below 0.6 mEq/L. The blind was maintained by having all subjects take an extra pill during the second week that was filled either with placebo or 300 mg of lithium. The 17-item HDRS (6) was used as the outcome measure. 
Results
The 36 subjects participating in the study included 6 men and 30 women ranging in age from 23 to 52 years. Demographic and clinical details of the sample are in Table 1 .
By ANCOVA there was a significant main effect of time (F = 10.34, df 1, P = 0.003), indicating a significant improvement in depression scores over the 2 weeks of the study. However, there was no significant main effect of group (F = 0.551, df 3, P = 0.651), indicating no significant difference in change in mean HDRS scores between the different groups. These data are shown in Figure 1 .
Discussion
We performed a preliminary study to assess the differences in outcome of augmentation with the combination of T3 and lithium, compared with either agent alone or with placebo, in patients with major depressive disorder. There was no significant difference in outcome of the combination compared with either treatment alone, although significant reductions in depression scores occurred across all groups. In fact, there was no significant difference between placebo and the active treatment groups. This is problematic, given the data to support the efficacy of lithium (1) and T3 (2) . This failure to demonstrate group differences may be explained by several factors: First, the sample size was small, so the lack of significant difference could be owing to a type II error. Second, the treatment duration was relatively short. Although separation of lithium and T3 augmentation from placebo has been demonstrated in a prior 2-week study (7), more substantial separation might have been demonstrated if the study had been extended.
Future studies designed to determine differential responses to different augmenting agents and their combination should involve larger numbers, over longer periods of time, and with as few active treatments as possible. Clearly, using a placebo control is essential in these types of studies. Méthodes : Nous avons mené une étude pilote randomisée de 2 semaines, à double insu et contrôlée par placebo de l'ajout de lithium comparé avec la T3, puis comparé avec la combinaison des 2 chez des sujets souffrant de trouble dépressif majeur qui n'avaient pas répondu à un antidépresseur.
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Résultats : Tous les groupes se sont significativement améliorés au cours des 2 semaines de traitement, mais il n'y avait pas de différences intergroupes significatives.
Conclusion :
Il n'y a peut-être pas d'avantage à combiner ces 2 agents d'augmentation, même si nous n'avons pas réussi à démontrer une séparation entre les traitements actifs et le placebo.
